(Translated by https://www.hiragana.jp/)
Methylergometrine: Revision history - Wikipedia Jump to content

Methylergometrine: Revision history


For any version listed below, click on its date to view it. For more help, see Help:Page history and Help:Edit summary. (cur) = difference from current version, (prev) = difference from preceding version, m = minor edit, → = section edit, ← = automatic edit summary

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)

16 May 2024

21 April 2024

8 March 2024

10 January 2024

3 December 2023

2 August 2023

14 February 2023

  • curprev 13:5113:51, 14 February 2023156.25.4.251 talk 15,784 bytes −6 The study state indeed that Methylergometrine cause cardiac valvulopathy, but this is only based on the fact that Methylergometrine (a 5-HT2B agonist) is an active metabolite of Methysergide, which is linked to fibrosis and is a 5-HT2b antagonist. undo

8 December 2022

2 October 2022

22 August 2022

18 April 2022

15 January 2022

20 October 2021

4 October 2021

14 August 2021

  • curprev 17:4917:49, 14 August 2021Citation bot talk contribs 14,180 bytes +227 Alter: title, template type. Add: archive-date, archive-url, chapter-url, isbn, chapter, s2cid, authors 1-1. Removed or converted URL. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Josve05a | Linked from User:Josve05a/cite/wayback | #UCB_webform_linked 579/1938 undo

4 May 2021

20 April 2021

16 April 2021

14 April 2021

13 April 2021

12 April 2021

19 October 2020

30 August 2020

19 June 2020

27 December 2019

26 December 2019

21 September 2019

2 May 2019

12 December 2018

10 May 2018

(newest | oldest) View (newer 50 | ) (20 | 50 | 100 | 250 | 500)